Flora Growth Corp. Announces Launch of Global Clinical Trials

Flora Growth Corp. (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global products and brands, has announced its entry into an agreement to begin scientific clinical trials globally. According to the update, the focus of this study will be on the use of cannabinoids in suffering from fibromyalgia or chronic pain, with primary research sites located in the United States and the United Kingdom.

By running phase trials in parallel (in vitro, in vivo, a pilot in human, safety/efficacy, etc.), Flora Pharma expects to fast-track traditional FDA and NHS timelines. “A paradigm shift is upon us where health care practitioners, researchers, patients, and adult-use consumers are starting to understand, accept and embrace the therapeutic potential offered by phytocannabinoid-based medicine. As such, there is an urgent need for more research to better understand the molecular and biochemical effects of at the cellular level, to begin to apply its implications as a pharmaceutical drug,” said Dr. Annabelle Manalo-Morgan, director and lead scientific advisor of Flora Growth. “I’m extremely pleased that our team recognizes the importance and necessity of this research, not only to create and bring to …

Full story available on Benzinga.com

More Flora Growth Corp. Announces Launch of Global Clinical Trials